JP2013513377A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513377A5
JP2013513377A5 JP2012542587A JP2012542587A JP2013513377A5 JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5 JP 2012542587 A JP2012542587 A JP 2012542587A JP 2012542587 A JP2012542587 A JP 2012542587A JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5
Authority
JP
Japan
Prior art keywords
identity
functionally equivalent
component
equivalent variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513377A (ja
JP5784626B2 (ja
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed filed Critical
Priority claimed from PCT/ES2010/070818 external-priority patent/WO2011070214A2/es
Publication of JP2013513377A publication Critical patent/JP2013513377A/ja
Publication of JP2013513377A5 publication Critical patent/JP2013513377A5/ja
Application granted granted Critical
Publication of JP5784626B2 publication Critical patent/JP5784626B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542587A 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物 Expired - Fee Related JP5784626B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (3)

Publication Number Publication Date
JP2013513377A JP2013513377A (ja) 2013-04-22
JP2013513377A5 true JP2013513377A5 (OSRAM) 2014-01-30
JP5784626B2 JP5784626B2 (ja) 2015-09-24

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542587A Expired - Fee Related JP5784626B2 (ja) 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物

Country Status (11)

Country Link
US (1) US8771664B2 (OSRAM)
EP (1) EP2511294B1 (OSRAM)
JP (1) JP5784626B2 (OSRAM)
CN (1) CN102753574B (OSRAM)
AU (1) AU2010329805B2 (OSRAM)
BR (1) BR112012013868A8 (OSRAM)
CA (1) CA2783876C (OSRAM)
ES (1) ES2463016T3 (OSRAM)
MX (1) MX2012006691A (OSRAM)
RU (1) RU2597989C2 (OSRAM)
WO (1) WO2011070214A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501805B (zh) 2011-01-18 2018-09-14 比奥尼斯有限责任公司 调节γ-C-细胞因子活性的组合物及方法
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN109395064A (zh) * 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
US10777298B2 (en) 2013-10-13 2020-09-15 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders
CN113637692A (zh) 2014-01-15 2021-11-12 卡德门企业有限公司 免疫调节剂
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
WO2016200881A1 (en) 2015-06-10 2016-12-15 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
PT3359556T (pt) 2015-10-09 2021-08-30 Bioniz Llc Modulação da atividade de citocinas gama-c
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス, インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
CN113874075A (zh) 2019-05-03 2021-12-31 比奥尼斯有限责任公司 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响
US20250281583A1 (en) * 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
PT814838E (pt) 1995-03-08 2003-09-30 Scripps Research Inst Sistema de apresentacao de antigenio e activacao de celulas t
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
CA2428114C (en) 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US9139611B2 (en) 2006-07-13 2015-09-22 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物

Similar Documents

Publication Publication Date Title
JP2013513377A5 (OSRAM)
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2013541335A5 (OSRAM)
JP2017532045A5 (OSRAM)
JP2009506762A5 (OSRAM)
JP2019506843A5 (OSRAM)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2014500868A (ja) 癌及び慢性感染の治療のための作動薬活性を有するil−2由来のポリペプチド
JP2019531093A5 (OSRAM)
JP2011502479A5 (OSRAM)
JP2014510519A5 (OSRAM)
JP2010516290A5 (OSRAM)
FI3642340T3 (fi) Muunneltu l-asparaginaasi
JP2014523238A5 (OSRAM)
JP2010506826A5 (OSRAM)
JP2013505734A5 (OSRAM)
CN101143894A (zh) 高效抑制血管生成多肽及其物理化学修饰方法和应用
JP2013515745A5 (OSRAM)
JP2017529326A5 (OSRAM)
JP2009112314A5 (OSRAM)
JP2015522264A5 (OSRAM)
RU2009104749A (ru) Рекомбинантные белки, подобные человеческому интреферону
JP2018506287A5 (OSRAM)